Are These Stocks Long Term Opportunities? Megola Inc (MGON), BirchCliff Energy New (BIREF) and Amarantus Bioscience Holdings Inc (AMBS)

Posted by Saimoon March 27, 2015 0 Comment 837 views


New York, NY – GDP INSIDER  –  03/27/2015.

This article discusses three companies: Megola Inc (OTCMKTS:MGON), BirchCliff Energy New (OTCMKTS:BIREF) and Amarantus Bioscience Holdings Inc (OTCBB:AMBS)

Megola Inc (OTCMKTS:MGON) skyrocketed today with the stock climbing 288.24% or $0.0049 to close at $0.0066 on extremely active trading of 90.079 million shares, compared to its three month average trading volume of 5.402 million. The manufacturer of fire inhibitor coating and powder products has been in steady decline for most of the last 52 weeks. The stock was enjoying a strong rally a year ago, when its technology was converted to be used to help medical marijuana to grow indoors. At this price the stock is an interesting medium to long term speculative investment.

Is Megola Inc A Savvy Investment? Take A Closer Look At The Fundamentals With Free MGON Analysis.

BirchCliff Energy New (OTCMKTS:BIREF) continued its slow climb yesterday with the stock gaining another 2.40% or $0.13 to close at $5.54 on active trading volume of 0.146 million shares, compared to its three month average trading volume of 0.033 million. The developer and producer of oil and natural gas has been declining the past three months like most companies in the sector, due to the falling price of oil and other energy commodities. Despite the difficult trading environment the stock has now gained 1.77% this month so far and may go higher making it a hold.

Can BirchCliff Energy New Maintain Its Trend In The Medium Term? Click Here For Free BIREF Analysis.

Amarantus Bioscience Holdings Inc (OTCBB:AMBS) bounced back yesterday with the stock gaining 16.67% or $0.0085 to close at $0.0595 with more than 9.437 million shares changing hands, compared to its three month average trading volume of 5.226 million. The researcher and developer of treatments associated with biological pathways started gaining after it announced that it has a new active investigational drug application with the FDA, to start Phase 2b testing of its Parkinson disease treatment drug eltoprazine. Once approved, the clinical study could start next quarter and if it is successful, could drive the shares much higher long term.

Are Amarantus Bioscience Holdings Inc’s Technical Indicators Strong Enough? Take A Closer Look With Free AMBS Analysis.

About UltimateStockAlerts

UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.


Write Your Comment